JP2022543231A5 - - Google Patents
Info
- Publication number
- JP2022543231A5 JP2022543231A5 JP2022506574A JP2022506574A JP2022543231A5 JP 2022543231 A5 JP2022543231 A5 JP 2022543231A5 JP 2022506574 A JP2022506574 A JP 2022506574A JP 2022506574 A JP2022506574 A JP 2022506574A JP 2022543231 A5 JP2022543231 A5 JP 2022543231A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- bispecific compound
- hydrogen
- group
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882958P | 2019-08-05 | 2019-08-05 | |
| US62/882,958 | 2019-08-05 | ||
| PCT/US2020/044815 WO2021026109A1 (en) | 2019-08-05 | 2020-08-04 | Degraders of cyclin-dependent kinase 7 (cdk7) and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022543231A JP2022543231A (ja) | 2022-10-11 |
| JP2022543231A5 true JP2022543231A5 (enExample) | 2023-08-02 |
| JP7636388B2 JP7636388B2 (ja) | 2025-02-26 |
Family
ID=74503218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506574A Active JP7636388B2 (ja) | 2019-08-05 | 2020-08-04 | サイクリン依存性キナーゼ７（ｃｄｋ７）の分解誘導剤およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12491251B2 (enExample) |
| EP (1) | EP4010336B1 (enExample) |
| JP (1) | JP7636388B2 (enExample) |
| CN (1) | CN114174281B (enExample) |
| AU (1) | AU2020324408B2 (enExample) |
| CA (1) | CA3149374A1 (enExample) |
| ES (1) | ES3031581T3 (enExample) |
| WO (1) | WO2021026109A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| EP3810132A4 (en) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | TAIRE FAMILY KINASE INHIBITORS AND RELATED USES |
| CN113164477A (zh) | 2018-12-14 | 2021-07-23 | 达纳-法伯癌症研究所股份有限公司 | C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途 |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF |
| CA3166135A1 (en) * | 2019-12-24 | 2021-07-01 | Dana-Farber Cancer Institute, Inc. | The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer |
| CN117242060B (zh) | 2021-01-13 | 2026-07-17 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮化合物 |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| CN113234081A (zh) * | 2021-05-27 | 2021-08-10 | 东南大学 | 一种吡咯并吡唑衍生物与dmpeda做脲的制备方法 |
| WO2022248682A1 (en) * | 2021-05-28 | 2022-12-01 | Qurient Co., Ltd. | Compounds for degradation of cyclin-dependent kinase 7 (cdk7) |
| CN116396295A (zh) * | 2023-04-04 | 2023-07-07 | 合肥工业大学 | 一种基于protac的plk1降解剂的合成方法 |
| WO2025252190A1 (en) * | 2024-06-07 | 2025-12-11 | Cullgen Inc. | Targeted degraders of werner syndrome recq helicase |
| CN119119072B (zh) * | 2024-08-23 | 2025-10-03 | 武汉大学 | 一种用于检测和降解ERα的诊疗一体化ERαPROTACs化合物及其制备方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2416527C (en) | 2000-08-10 | 2009-12-22 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US9345705B2 (en) | 2011-09-15 | 2016-05-24 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| WO2013070688A1 (en) | 2011-11-11 | 2013-05-16 | Yale University | Reprogramming urokinase into an antibody-recruiting anticancer agent |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| US10870651B2 (en) * | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| AU2016232705C1 (en) * | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| AU2016281225B2 (en) * | 2015-06-15 | 2020-10-15 | Ube Corporation | Substituted dihydropyrrolopyrazole derivative |
| BR112018008918A8 (pt) | 2015-11-02 | 2019-02-26 | Univ Yale | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos |
| AU2017254702B2 (en) | 2016-04-22 | 2020-12-24 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use |
| CN121974842A (zh) * | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CA3045037A1 (en) * | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| CN109516989B (zh) | 2017-09-17 | 2021-12-31 | 上海美志医药科技有限公司 | 一类抑制并降解cdk的化合物 |
-
2020
- 2020-08-04 CN CN202080050815.4A patent/CN114174281B/zh active Active
- 2020-08-04 EP EP20849357.7A patent/EP4010336B1/en active Active
- 2020-08-04 WO PCT/US2020/044815 patent/WO2021026109A1/en not_active Ceased
- 2020-08-04 AU AU2020324408A patent/AU2020324408B2/en active Active
- 2020-08-04 ES ES20849357T patent/ES3031581T3/es active Active
- 2020-08-04 US US17/631,774 patent/US12491251B2/en active Active
- 2020-08-04 JP JP2022506574A patent/JP7636388B2/ja active Active
- 2020-08-04 CA CA3149374A patent/CA3149374A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023520333A5 (enExample) | ||
| JP2022512900A5 (enExample) | ||
| JP5324574B2 (ja) | Ｃ型肝炎の治療に有用な化合物の合成方法 | |
| IL281503A (en) | Preparations and methods for preventing Arginase activity | |
| US20090041716A1 (en) | Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt | |
| IL296994A (en) | Compounds and uses thereof | |
| JP2024519140A5 (enExample) | ||
| JP2009530424A5 (enExample) | ||
| RU2020108523A (ru) | Гетероарил-замещенные бета-гидроксиэтиламины для применения для лечения гипергликемии | |
| JP2005505507A (ja) | 抗感染活性を有するイソキノリン化合物 | |
| CZ20031380A3 (cs) | LFA-1 Antagonistické sloučeniny | |
| JP2010510301A (ja) | 化合物 | |
| JP2022510505A5 (enExample) | ||
| JP2024521919A5 (enExample) | ||
| JP2000503999A (ja) | ジスタマイシン誘導体、その調製方法、および抗腫瘍および抗ウイルス剤としてのその使用 | |
| JP2000510129A (ja) | ジスタマイシン誘導体、その調製方法並びに抗腫瘍薬及び抗ウイルス薬としてのその使用 | |
| NL1027545C2 (nl) | Chinolonen als antibacteriele middelen. | |
| US20250243211A1 (en) | Processes and intermediates for producing diazaspiro lactam compounds | |
| EP3578179A1 (en) | Process for the preparation of cyclic depsipeptides | |
| AU2020348825B2 (en) | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof | |
| CN105399737B (zh) | 噁唑烷酮类化合物及其用途 | |
| JP4149172B2 (ja) | インテグリンと受容体との結合を阻害するカルボン酸誘導体 | |
| JP2003515586A (ja) | アクリロイルペプチド誘導体、その調製法、およびその抗腫瘍薬としての使用 | |
| HUT75114A (en) | 1-oxo-2-(phenylsulfonyl-amino)-pentylpiperidine derivatives, process for producing them and pharmaceutical use of them | |
| JPH01199983A (ja) | 新規珪素含有ペプチド類、それらの製法および用途 |